In Brief: FDA Anti-Infective Drug Products Division
FDA Anti-Infective Drug Products Division: Director Mary Fanning MD/PhD resigns after less than a year at the agency. Fanning, an AIDS researcher, joined the agency in July 1995 from Toronto's Wellesley Hospital ("The Pink Sheet" April 3, 1995 In Brief). Effective July 5, Office of Drug Evaluation IV Acting Director David Feigal, MD, will serve as acting director of the anti-infectives division. Donna Freeman, MD, will fill Feigal's other roles as acting director of the Division of Antiviral Drug Products...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth